GlaxoSmithKline, development phase

The noradrenaline and dopamine reuptake inhibitor bupropion (GlaxoSmithKline) is currently in clinical development (phase II) for neuropathic pain. 

Class 1 drugs represent a subset of drugs that is decreasing with time If the orally administered immediate release products in the List of Essential Medicines of the World Health Organization (WHO) are considered, approximately 30% can be considered as class 1 drugs (97,98). However, the proportion of class 1 compounds in the development phase for oral immediate-release formulations at AstraZeneca was less than 10% in 2001 (99), and is sHghtly less than 20% at GlaxoSmithKline (100). 

Although no PPARS-specific ligands are currently FDA-approved, GW501516 is a compound being developed jointly by GlaxoSmithKline and Ligand Pharmaceuticals. This compound is currently in Phase II trials for the treatment of dyslipidemia. 

It is intereshng that 12 of the previous 15 chapter authors in this book have menhoned the E factor, which shows how embedded the concept has become in the pharmaceutical industry. Eurthermore, in 2007 GlaxoSmithKline (GSK) became the first company to set E factor goals (or its equivalent, mass productivity ) across its phase-three development compounds and to pubhsh those goals on... 

---